Sign Out
Adult onset Still’s disease, Systemic onset juvenile chronic arthritis
Adult: As monotherapy or in combination with methotrexate in patients with inadequate response to NSAIDs and corticosteroids: 4 mg/kg as single dose every 4 weeks. Max: 300 mg.
Child: ≥2 years weighing ≥7.5 kg: Same as adult dose.
Child: ≥2 years weighing ≥7.5 kg: Same as adult dose.
Subcutaneous
Deficiency of mevalonate kinase, Hyper-immunoglobulin D periodic fever syndrome, Tumour necrosis factor receptor-associated periodic fever syndrome
Adult: ≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as a single dose every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: ≥2 years weighing 7.5-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: ≥2 years weighing 7.5-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Subcutaneous
Familial amyloid nephropathy with urticaria and deafness, Familial cold urticaria, Neonatal onset multisystem inflammatory disease
Adult: ≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 8 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: 2-<4 years weighing 7.5-<15 kg: 4 mg/kg; ≥4 years weighing 15-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 8 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: 2-<4 years weighing 7.5-<15 kg: 4 mg/kg; ≥4 years weighing 15-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 8 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Subcutaneous
Familial Mediterranean fever
Adult: In combination with colchicine: ≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given as single dose every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: In combination with colchicine: ≥2 years weighing 7.5-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Child: In combination with colchicine: ≥2 years weighing 7.5-≤40 kg: 2 mg/kg; >40 kg: 150 mg. All doses given every 4 weeks. Dose modification, or discontinuation may be required according to individual safety, tolerability and response (refer to detailed product guideline).
Subcutaneous
Acute gout
Adult: In patient contraindicated to NSAID and colchicine with at least 3 attacks within the last 12 months: 150 mg as a single dose, given as soon as possible after the onset of an attack. Discontinue if no response. If symptoms recur after initial response, repeat dose after at least 12 weeks.
